Long-term Aspirin Therapy as a Predictor of Decreased Susceptibility to SARS-CoV-2 Infection in Aspirin-Exacerbated Respiratory Disease (AERD-CoV19)
AERD - Aspirin Exacerbated Respiratory Disease
About this trial
This is an interventional treatment trial for AERD - Aspirin Exacerbated Respiratory Disease
Eligibility Criteria
Inclusion Criteria: INCLUSION CRITERIA FOR AERD PATIENTS: signed informed consent form 18-70 years old AERD patients with baseline FEV1 of at least 70% of the predicted value on the challenge/desensitization day no pregnancy, higly effective contraception must be used INCLUSION CRITERIA FOR HEALTHY CONTROL: signed informed consent form 18-70 years old and healthy condition no asthma Exclusion Criteria: failure of the circulatory and respiratory system, liver, kidneys and other vital organs diabetes, cancer, systemic diseases of connective tissue, infectious diseases, coagulation disorders, active peptic ulcer disease, any active bleeding process. Use of drugs that interact with aspirin use of intoxicants, alcohol abuse, active and passive smoking, pregnancy, lactation. hypersensitivity to the active substance or any of the excipients
Sites / Locations
- University Hospital, Pulmunology ClinicRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Aspirin
Placebo
Acard 300 mg (Acidum acetylsalicylicum). 1 tablet (300 mg) twice a day
Placebo 1 tablet twice a day